NewsCorporate ActionsBajaj Healthcare Expands with Genrx Pharmaceuticals Acquisition, Considers Bonus SharesBajaj Healthcare Expands with Genrx Pharmaceuticals Acquisition, Considers Bonus Shares
By ScanX News Team
Bajaj Healthcare Limited has acquired Genrx Pharmaceuticals Private Limited for ₹10.85 crore in an all-cash deal, gaining 100% control. The acquisition, completed on April 4, 2025, aims to expand Bajaj Healthcare's manufacturing capabilities. Genrx Pharmaceuticals is a WHO-GMP certified manufacturer specializing in allopathic formulations, nutraceuticals, and natural products. The integration is expected to take 3-6 months, pending regulatory approvals. Additionally, Bajaj Healthcare's board will meet on April 16 to consider issuing bonus shares.
*this image is generated using AI for illustrative purposes only.
Bajaj Healthcare Limited has made a strategic move to expand its manufacturing capabilities by acquiring Genrx Pharmaceuticals Private Limited for ₹10.85 crore in an all-cash deal. The acquisition grants Bajaj Healthcare 100% control of the target entity, marking a significant step in the company's growth strategy.
Acquisition Details
According to a recent press release, Bajaj Healthcare completed the acquisition of Genrx Pharmaceuticals as a going concern on April 4, 2025. The official sale certificate was issued by the Official Liquidator, confirming the transaction's completion.
About Genrx Pharmaceuticals
Genrx Pharmaceuticals, incorporated in 2009 and based in Thane, Maharashtra, is a WHO-GMP certified pharmaceutical manufacturer. The company specializes in producing allopathic formulations, nutraceuticals, and natural products. Its manufacturing facility, located at MIDC Sinnar, Nashik, is capable of producing various dosage forms, including:
- Solid dosage forms (tablets and capsules)
- Semi-solid dosage forms
- External preparations
- Cosmetic products
- Nasal sprays
Strategic Implications
Mr. Anil Jain, Managing Director of Bajaj Healthcare Limited, commented on the acquisition: "The acquisition of Genrx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities. This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth."
The acquisition is expected to be fully integrated within 3-6 months, subject to necessary FDA and other regulatory approvals. This expansion is anticipated to broaden Bajaj Healthcare's manufacturing portfolio and strengthen its position in the pharmaceutical sector.
Potential Bonus Share Issuance
In a separate development, Bajaj Healthcare's board is scheduled to meet on April 16 to consider a proposal for issuing bonus shares. This consideration comes on the heels of the acquisition announcement, potentially signaling the company's confidence in its growth trajectory.
Insider Trading Window
As per SEBI regulations and the company's internal procedures, Bajaj Healthcare has announced that the trading window for dealing in the company's securities will remain closed for all Directors and Designated Employees. This closure is in line with the company's earlier disclosure dated March 25, 2025.
Outlook
The acquisition of Genrx Pharmaceuticals and the potential bonus share issuance reflect Bajaj Healthcare's strategic initiatives to enhance its market position and create value for shareholders. As the company integrates its new acquisition and explores further growth opportunities, investors and industry observers will be keenly watching for the outcomes of these developments in the coming months.
Investors are advised to keep an eye on further announcements from the company, particularly regarding the outcome of the board meeting scheduled for April 16, which will address the bonus share proposal.
Historical Stock Returns for Bajaj HealthCare
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.04% | +7.45% | -6.30% | +65.27% | +94.09% | +71.41% |
